Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab 40mg weekly vs 80mg every two weeks in IBD
NCT04404517Phase 3Unknown
- Sponsor
- Hospital Universitario La Paz
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in inflammatory bowel disease (IBD), sponsored by Hospital Universitario La Paz. Status: unknown.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04404517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404517.